McKesson Corporation (MCK) Total Return:3.40%(TTM)
Over the latest trailing 12-month period, McKesson Corporation (MCK)'s total return cagr is +3.40%. The comparable SPY value is +26.54%. Year-to-date total return is -8.31%. Total return includes price appreciation and reinvested dividends.
Growth of $10,000 in MCK
$393,287
(39.3x return)
Invested on Jun 19, 1996
Growth of $10,000 in SPY (S&P 500)
$186,318
(18.6x return)
Invested on Jun 19, 1996
Hypothetical Growth of $10,000
This chart illustrates the cumulative performance of a hypothetical $10,000 investment. It assumes that all dividends paid by both the stock and SPY are reinvested in additional shares on the payment date, showing the true long-term compounding impact of distributions.
Recent Performance Indicators
YTD Total Return
-8.3%
1-Year Total Return
+3.4%
Current Dividend Yield
0.44%
Price CAGR vs. Total Return CAGR
Compound Annual Growth Rate (CAGR) is shown below. The difference between price CAGR and total return CAGR is the compound contribution of dividends reinvested.
| Holding Period | Price CAGR | Total Return CAGR | Dividend Addition |
|---|---|---|---|
| 1 Year | +3.0% | +3.4% | +0.4% |
| 3 Years | +22.7% | +23.2% | +0.6% |
| 5 Years | +32.4% | +33.1% | +0.7% |
| 10 Years | +15.5% | +16.4% | +0.9% |
| 15 Years | +15.9% | +16.7% | +0.9% |
| 20 Years | +15.0% | +15.9% | +0.9% |
About McKesson Corporation
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
- Sector
- Healthcare
- Industry
- Medical - Distribution
- CEO
- Brian S. Tyler